Working with a dedicated market access and health economics and outcomes research (HEOR) consultancy offers significant added value to Pharma and Medical Device companies and can give you the confidence...
Read More
Last month, our evidence team tuned in to watch the Virtually Cochrane conference. Each year the Cochrane conference explores the latest thought leadership in systematic review and healthcare evidence. This...
Read More
Nine of our senior team made the trip to Copenhagen to represent Mtech Access at ISPOR Europe this November. The conference brought together leading experts from across Health Economics and Outcomes...
Read More
‘Time to event’ or ‘survival’ is an important endpoint used in efficacy assessments of medical interventions, particularly in disease areas such as oncology. The Cox proportional hazards (PH) model is…
Continuous outcomes data from trials may be categorised using pre-defined cut-offs to generate ordered categorical outcomes data. Usually the percentage of patients who have improved by certain thresholds are reported…
Network meta-analysis (NMA) is a key tool for researchers and decision makers that allows the efficacy and safety of any number of healthcare interventions to be compared simultaneously. However, a…
